The Efficacy of Melatonin in Intrauterine Growth Restriction

The Efficacy of Melatonin in Intrauterine Growth Restriction, A Double blind Randomized Clinical Trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170515033976N3

Enrollment

Registered

2026-03-14

Start date

2026-04-04

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intrauterine Growth Restriction (IUGR) / Fetal Growth Restriction (FGR). Disorders of newborn related to slow fetal growth and fetal malnutrition

Interventions

Intervention 1: Intervention group: Oral prolonged-release melatonin tablets, 10 mg, three times daily, from enrolment until delivery. Manufacturer: Abidi Pharmaceutical Company, Iran. Intervention 2:

Eligibility

Sex/Gender

Female

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Singleton pregnancy 28 weeks and over of gestation Intrauterine Growth Restriction

Exclusion criteria

Exclusion criteria: Current use of melatonin Pregnancies requiring immediate delivery A history of systemic diseases A history of smoking Contraindications to melatonin use

Design outcomes

Primary

Measure	Time frame
Estimated fetal weight. Timepoint: weekly. Method of measurement: Sonography.;Fetal Doppler. Timepoint: weekly. Method of measurement: Sonography.;Birth weight. Timepoint: After birth. Method of measurement: Scale.	—

Secondary

Measure	Time frame
Umbilical cord blood gases. Timepoint: After birh. Method of measurement: Analyzer.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElham Gorjipour

Shiraz University of Medical Sciences

e.gorjipour????@gmail.com+98 71 3647 9830

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026